Physician profile
Ghassan Koussa
NPI 1730341421
$9,362.98
in general payments reported to CMS, 2019-2025
38 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $388 · 2021: $994 · 2022: $1,736 · 2023: $772 · 2024: $2,089 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,240 · Travel and Lodging: $289 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,240.25 |
| Travel and Lodging | $289.46 |
| Education | $106.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,643.12 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,989.26 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.80 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $609.46 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $479.31 | 2021-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $373.78 | 2022-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $366.36 | 2020-2025 | |
| Amgen INC. | $318.28 | 2021-2025 | Tezspire |
| Philips North America LLC | $203.33 | 2023-2024 | (Ak6) Vest Therapy |
| Intuitive Surgical, INC. | $177.35 | 2025 | |
| Insmed, INC. | $147.17 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $134.78 | 2021-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $133.28 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $122.74 | 2025 | Acthar |
| Medical Device Business Services, INC. | $112.11 | 2025 | Monarch |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $101.80 | 2021 | |
| Ethicon INC. | $88.42 | 2025 | Monarch Platform |
| Novartis Pharmaceuticals Corporation | $83.68 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Abbvie INC. | $61.65 | 2024-2025 | |
| Verona Pharma, INC. | $58.17 | 2025 | Ohtuvayre |
| Pfizer INC. | $53.36 | 2022-2023 | |
| Fisher & Paykel Healthcare INC | $38.22 | 2024 | Fisher & Paykel Healthcare |
| United Therapeutics Corporation | $33.71 | 2025 | Tyvaso |
| Medtronic, INC. | $29.13 | 2025 | Illumisite |
| Circassia INC. | $28.30 | 2019 | |
| Genentech USA, INC. | $27.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $24.28 | 2025 | Nuzyra |
| Olympus America INC. | $23.28 | 2023 | Spin Thoracic Navigation System, 120v, 60hz |
| Electromed, INC. | $23.17 | 2022 | |
| Ambu INC. | $23.03 | 2025 | |
| Pharming Healthcare, INC. | $21.17 | 2024 | Ruconest |
| Csl Behring | $19.96 | 2020 | |
| Inogen, INC. | $19.79 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.86 | 2023 | Glassia |
| Mallinckrodt Enterprises LLC | $17.69 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghassan Koussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.